PALVELLA THERAPEUTICS

Company snapshot

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PALVELLA THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for PALVELLA THERAPEUTICS.

1. May 23, 2026 Clinical update

   PTX-022 — Phase 3

2. May 23, 2026 Clinical update

   QTORIN 3.9% Rapamycin Anhydrous Gel — Phase 3

3. May 23, 2026 Clinical update

   QTORIN 3.9% rapamycin anhydrous gel — Phase 3

4. May 23, 2026 Clinical update

   PTX-022 — Phase 2

5. May 23, 2026 Clinical update

   PTX-022 — Phase 2

View all clinical trial activity →

• What is PALVELLA THERAPEUTICS?

  PALVELLA THERAPEUTICS is a pharma organization headquartered in Wayne, USA. It trades on NYSE under ticker PVLA. Primary therapeutic focus areas include Microcystic Lymphatic Malformation, Pachyonychia Congenita, Angiokeratomas, BCCs in Gorlin Syndrome Patients, Cutaneous Venous

• Is PALVELLA THERAPEUTICS publicly traded?

  Yes. PALVELLA THERAPEUTICS is listed with ticker PVLA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does PALVELLA THERAPEUTICS develop or market?

  No drug profiles are currently linked to PALVELLA THERAPEUTICS. Pipeline programs may still list investigational assets.

• What are the latest developments for PALVELLA THERAPEUTICS?

  In the last 12 months our linked public records show 7 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does PALVELLA THERAPEUTICS focus on?

  PALVELLA THERAPEUTICS focuses on Microcystic Lymphatic Malformation, Pachyonychia Congenita, Angiokeratomas based on our analysis of their pipeline programs and drug development activities.